4DMT (FDMT): Multiplikator P/S
The revenue multiple dynamics demonstrate the market valuation of 4D Molecular Therapeutics (FDMT), where 7.20 represents the latest metric reading. The gene therapy developer relies on stable demand, although equipment logistics and patent protection remain dependent on geopolitics. The hereditary pathology treatment sector is non-cyclical, and business success is based on the clinical validation of vectors and sufficient liquidity reserves.
Rincian analitis perusahaan 4D Molecular Therapeutics
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi bursa:
- data ekuitas miturut neraca:
- statistik kawajiban utang lan likuiditas:
Rasio Total Utang marang Ekuitas 4D Molecular Therapeutics|FDMT - Rasio silihan jangka dawa marang modal|Utang jangka cendhak marang modal 4dmoleculartherapeutics.com|FDMT - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku 4D Molecular Therapeutics Inc|FDMT - Utang jangka dawa|Utang jangka cendhak perusahaan 4D Molecular Therapeutics|Rasio cepet 4dmoleculartherapeutics.com
- rincian asil keuangan lan kelipatan valuasi:
FDMT - Bathi resik|Bathi sing dikarepake 4D Molecular Therapeutics|FDMT - Kapitalisasi marang bathi resik|Pangali Forward P/E 4D Molecular Therapeutics, Inc.|FDMT - Rega marang bathi kanthi panyesuaian wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan 4D Molecular Corp|FDMT - Bathi operasional EBITDA|Bathi resik saben saham sajrone 12 wulan pungkasan 4D Molecular Therapeutics|FDMT - Bathi saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan 4dmoleculartherapeutics.com|FDMT - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep 4D Molecular Therapeutics
- data pendapatan lan penerimaan dodolan:
Analisis dhasar perusahaan:FDMT 4D Molecular Therapeutics
The P/S ratio determines the market value of one dollar of revenue, allowing for an assessment of the asset's overvaluation in the absence of net profit. Analyzing the current P/S of 4D Molecular Therapeutics (FDMT) at 7.20, an investor sees a premium for the unique vector platforms of 4D Molecular Therapeutics (FDMT), which, thanks to patent protection, minimize pricing pressure from competitors and justify a high fundamental business valuation.
Analisis pesaing 4D Molecular Therapeutics
TEM (Tempus AI, Inc.) - Rasio kapitalisasi pasar marang pendapatan|Qiagen Group - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan IONS|RGEN - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Avidity Biosciences RNA|CRSP: Multiplikator P/S|Rasio kapitalisasi marang pendapatan WGS|RARE (Ultragenyx Pharma) - Multiplikator P/S|Multiplikator P/S Beam Therapeutics Inc.|Rasio rega marang pendapatan Sarepta Therapeutics Inc (SRPT)|Twist Bioscience - Rasio kapitalisasi marang pendapatan|10x Genomics Inc - Kapitalisasi marang pendapatan|NTLA (Intellia Therapeutics, Inc.) - Rasio rega marang dodolan|Stoke Corp - Multiplikator P/S|BLFS (BioLife) - Rasio kapitalisasi marang pendapatan|wavelifesciences.com (WVE) - Rasio rega marang pendapatan|MAZE - Koefisien rega marang pendapatan|SION (Sionna Therapeutics, Inc.) - Multiplikator P/S|Kapitalisasi marang pendapatan Prime Medicine Corp (PRME)|Multiplikator P/S TSHA|Multiplikator P/S uniQure N.V. (QURE)|Rasio rega marang pendapatan MeiraGTx Holdings plc MGTX|RGNX: Rasio kapitalisasi marang pendapatan|Solid Biosciences Inc - Multiplikator P/S|OCGN - Multiplikator P/S|PACB: Multiplikator P/S|BNTC - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Design Therapeutics, Inc.|RCKT: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Lexeo (LXEO)|KRRO (Korro Bio Inc.) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S EDIT (Editas Medicine, Inc.)|Multiplikator P/S Silence Therapeutics Corp SLN|PRQR - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Codexis Inc CDXS|SGMO: Multiplikator P/S|Rasio kapitalisasi marang pendapatan NAUT|Rasio rega marang pendapatan metagenomi.co|Multiplikator P/S Precision BioSciences Inc.|Multiplikator P/S GBIO|Boundless Bio, Inc. - Rasio kapitalisasi marang pendapatan|Multiplikator P/S XCUR (Exicure, Inc.)|Koefisien rega marang pendapatan Imunon, Inc. (IMNN)|PHIO - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan MBIO (mustangbio.com)|RNAZ: Multiplikator P/S|Rasio kapitalisasi marang pendapatan BNGO|APDN (Applied DNA Corp) - Multiplikator P/S|BLUE: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan ImmunoPrecise (IPA)|OMGA - Rega marang dodolan|Rasio rega marang pendapatan Singular Genomics OMIC|Rasio kapitalisasi pasar marang pendapatan RGLS|Syros Pharmaceuticals, Inc. - Multiplikator P/S|Koefisien rega marang pendapatan Telesis Bio Inc. TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Rasio rega marang pendapatan|Unity Biotechnology, Inc - Rasio kapitalisasi pasar marang pendapatan
